Article Text

Download PDFPDF

Decreasing efficacy of repeated intravitreal triamcinolone injections in diabetic macular oedema
  1. C K M Chan1,2,
  2. S Mohamed1,2,
  3. M P Shanmugam1,2,
  4. C-W Tsang1,2,
  5. T Y Y Lai1,2,
  6. D S C Lam1,2
  1. 1Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong
  2. 2Hong Kong Eye Hospital, 147K Argyle Street, Kowloon, Hong Kong
  1. Correspondence to: Professor Dennis S C Lam Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, University Eye Center, Hong Kong Eye Hospital, 147K, Argyle Street, Hong Kong; dennislam_pub{at}cuhk.edu.hk

Abstract

Background/aim: Intravitreal triamcinolone (IVTA) results in transient improvements in diabetic macular oedema (DMO), necessitating repeated injections. The authors report a case series of 10 eyes of 10 patients with DMO, who received a repeat injection of 4 mg IVTA, at least 26 weeks after the first injection of the same dose.

Method: Pre-injection and at 2, 4, 9, and 17 weeks post-injection, best corrected visual acuity (BCVA) and central foveal thickness (CFT) on optical coherence tomography, after the first and repeat injections, were compared using paired t test. Side effects were monitored.

Results: BCVA, CFT, intraocular pressure (IOP), and cataract scores were not significantly different before initial and repeat injections (given at 32.5 (SD 3.5) weeks after the first injection). Transient improvements of BCVA and CFT were achieved after both injections. However, after the repeat injection, the BCVA was significantly worse at all time points (p<0.05) and so were the best achieved CFT and the CFT at 4 weeks post-injection (p = 0.034 and 0.011 respectively), compared with the initial injection. Post-injection maximum IOPs and increase in cataract scores were not significantly different between the two injections.

Conclusion: A repeat injection of 4 mg of IVTA may not be as effective as an initial injection for the treatment of DMO.

  • BCVA, best corrected visual acuity
  • CFT, central foveal thickness
  • CSMO, clinically significant macular oedema
  • DMO, diabetic macular oedema
  • ETDRS, Early Treatment of Diabetic Retinopathy Study
  • IOP, intraocular pressure
  • IVTA, intravitreal triamcinolone
  • LOCS, Lens Opacity Classification System
  • OCT, optical coherence tomography
  • VEGF, vascular endothelial growth factor
  • diabetic macular oedema
  • triamcinolone acetonide
  • dose-response relation
  • BCVA, best corrected visual acuity
  • CFT, central foveal thickness
  • CSMO, clinically significant macular oedema
  • DMO, diabetic macular oedema
  • ETDRS, Early Treatment of Diabetic Retinopathy Study
  • IOP, intraocular pressure
  • IVTA, intravitreal triamcinolone
  • LOCS, Lens Opacity Classification System
  • OCT, optical coherence tomography
  • VEGF, vascular endothelial growth factor
  • diabetic macular oedema
  • triamcinolone acetonide
  • dose-response relation
View Full Text

Statistics from Altmetric.com

Footnotes

  • Financial support: nil.

  • Competing interests: nil.

  • Financial and proprietary interest: nil.

    Ethical approval: The patients in this study participated in clinical trials which had ethical approval from the Chinese University of Hong Kong Clinical Research Ethics Committee and the research was carried out according to the tenets of the Declaration of Helsinki. Informed consent was obtained from all patients.

    Presentation: The data in this paper were presented in part at the Annual Scientific Meeting of the Hong Kong Ophthalmological Society (3–5 Dec 2005, Hong Kong) and the 21st Congress of the Asia Pacific Academy of Ophthalmology (10–14 June 2006, Singapore).

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles